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Abstract 
The pharmaceutical industry is considered the most growing business. It has a huge 
profit margin and high investment in Research and Development to create new 
products to treat new diseases in addition to high investment in the marketing projects 
and sales power.  
Objectives – there are three main objectives of this paper: first purpose is to examine 
the globalisation in the pharmaceutical business, second purpose is to examine the 
opportunities in the Middle East pharmaceutical markets as a Pharmerging market and 
the third purpose is to examine the Jordanian pharmaceutical market as a future 
emerging market from a strategic point of view. The authors analyse the advantage / 
disadvantage ratio to penetrate the pharmaceutical Jordanian market. The authors 
suggest that penetrating Jordanian pharmaceutical market could be the gate to the 
whole Middle East region. 
Purpose: is to provide information for the pharmaceutical companies the latest data 
about the Pharmerging countries in the Middle East and long-term strategic decision 
in the region.    
Originality / Value – the article addresses the strategic importance for the 
pharmaceutical companies to consider when penetrating the MENA countries (Middle 
East and North Africa) 
Paper type – Presentation in the 3rd annual Pharma Forecasting Excellence 2010 in 
Boston, MA – USA 
  
Pharmaceutical industry 
The initial idea about the pharmaceutical industry started in late 1850s, and before 
that the disease was known as one of mankind's obsessions. It was known a black evil 
or an alien which enter the body and cause high fever, weakness, fatigue and might 
reach to death. People used to say that it is because of the past sins which affect the 
patients' social image in the community. Patients used to go to different places 
looking for treatment; they used to go churches, herbs experts and doctors.  
The emerging of pharmaceutical industry was breakthrough and the drug makers 
created this idea “You Have a Problem, We Have a Pill”. This idea makes the 
pharmaceutical business one of the world's largest industries and in addition to this it 
became the most profitable business. Since that time; the medicines industry is in a 
continuous development to serve humanity and prevent diseases (Lynn, 1992). 
The pharmaceutical business differs from any other business particularly when 
compared to the Fast Moving Consumer Goods (FMCG). Some of these differences 
are in their long patent life of the medicines, sophisticated research and development 
to produce new molecules, high development costs, highly profitable, highly 
controlled market and its promotion depends on scientific studies through which 
doctors and pharmacists contribute in the consumption decision of the drugs (Haloub, 
2007). 
Pharmaceutical products used to be divided into two main categories: Over the 
Counter (OTC) and Prescribed, but the new classification of the pharmaceutical 
products is: Over the Counter (OTC), Prescribed and Hybrid (could be both; OTC 
and/or prescribed). The Prescribed pharmaceuticals are divided into different 
segments (Dermatology, cardiology, …etc)  (Haloub, 2007) 
Each pharmaceutical company has its own image or identity, and it is basically 
depending on the types of products manufactured, which will give the pharmaceutical 
company the competitive advantage to expand in the same segment and at the same 
time, creating more loyal customers in the market. As shown in the Table (1) the 
summery of performance data from the world's major pharmaceutical manufacturers. 
 Company Drug sales 
(US$ billions) 
Operating 
Profit Margin 
(% revenue) 
Net profit or 
loss 
(% revenue) 
R&D 
% revenue 
Marketing and 
administration  
(%revenue)* 
Approximate share  
price movement (%) 
Market capitalisation,  
November, 2001  
($US billion) 
GlaxoSmithKline 23.38 30.70 28.00 N/A N/A 890 166.40 
Pfizer 22.57 39.30 16.50 17.10* 39.20 5,800 274.30 
Merck 20.22 57.20 29.20 11.60 15.90 7,200 149.20 
Bristol Myers Squibb 15.88 N/A 29.70 9.10* 22.60 4,700 108.00 
AstraZeneca 15.70 25.60 16.20 N/A N/A 450 (Since January, 1994) 81.50 
Aventis 14.90 19.40 -0.91 16.80 N/A 230 (Since January, 1994) 55.00 
Pharmacia 12.65 8.70 5.70 17.10 38.60 970 58.00 
Johnson and Johnson 11.95 34.90 40.20 15.90 38.20 17,000 185.80 
American home Products 10.80 27.10 -21.90 15.00 37.20 1,000 78.40 
Hoffmann-La Roche 10.47 33.20 48.90 18.10 N/A N/A N/A 
Novartis 1.42 N/A 40.90 18.30 N/A 100 (Since May, 2000) 95.40 
Eli Lilly 10.19 N/A 30.00 17.80 27.60 2,000 92.70 
 
Intellectual property rights and pharmaceutical products: 
R&D that is conducted by pharmaceutical firms is considered as an investment 
activity that should capitalised in its market value, by which the R&D output is 
considered as intangible assets and can be labeled as "Knowledge Stock". If the these 
assets have a positive contribution to the firms' future net cash flow, then the amount 
of knowledge stock will indicate the market value (Hall, Jaffe and Trajtenberg, 2001). 
The cost of R&D in pharmaceuticals is very high, and according to the office of 
technology assessment; the pharmaceutical industries in USA claim to invest of 
US$30.5 billion in Research and development during the year 2000 (Sheehan, 2001) 
and pharmaceutical company would be considered successful if it launches one 
molecule per every 10,000 developed molecules during drug research (Lynn, 1992). 
Globalisation 
Globalisation is relatively a new term in business (as it was internationalisation) when 
compared to the other business and financial studies. Globalisation (Ramirez, 2006) is 
a distinct phase of the general process of internationalisation.  
Pharmaceutical industry was the first industry that recognised the importance of 
global business and pharmaceutical industries were asked to register their medicines 
and sell overseas to fulfill the patients' needs to cure diseases. At the same time, the 
governments simplify the process of shipping. Unintentionally; the pharmaceutical 
industries became globally operating. (Lynn, 1992) 
Data refer to 2000 unless otherwise specified.* 1999 data  Between January 1990 to November 2001  
Source: http://www.finance.yahoo.com; http://www.pjbpubs.co.uk 
Table 1: Summery of erformance data from the world's major pharmaceutical manufacturers 
  
The globalisation of research in this definition is characterised by the growth of 
Foreign Direct Investment (FDI) (allowing MNCs to distribute their research 
activities world-wide) and an increase in the international division of labour through 
the emergence of worldwide intra- and inter-corporate research networks. The 
pharmaceutical companies tend to focus on globalisation of research. These facilities 
would then operate within inter-dependent intra-firm R&D networks. 
Pharmerging Markets in the Middle East 
The definition of the territory of the Middle East varies between experts' opinions; 
some consider the Middle East includes: all Arab countries, Iran, and Turkey whereas 
some experts consider the Middle East countries are Gulf, Levant, Egypt, Iran, and 
Turkey. The Middle East definition is a region that spans southwestern Asia, 
southeastern Europe, and northeastern Africa. It has no clear boundaries. 
Before we go through this study, I will define the terms that I will use; the Arab world 
countries are those that speak Arabic as a native and official language, the Middle 
East and North African (MENA) counties are those that include Arab countries in 
addition to Sudan, Iran and Turkey; where the Middle East countries are those which 
include Arab countries in the region plus Egypt, Turkey and Iran, as shown in Figure 
(1).  
In the Middle East region, there is a new challenge due to the different environmental 
changes in the roles and regulations and the economic and political map in the region 
(like in Iraq, Syria, Palestine, and Iran). The Middle East pharmaceutical market is 
considered a very attractive one for different types of industries especially for 
pharmaceutical companies. Too many changes in a short period of time would create 
huge business opportunities. There are about 16 countries in Middle East, 12 out of 
which are Arab countries who share language and religion. The source of income is 
mineral production (oil) and agriculture and the modern industrial manufacturing is 
still in its infancy. The current population of the Middle East exceeds 350 million and 
is expected to grow by more than 40% over the next 20 years 
 
 The local pharmaceutical manufacturers in the Middle East produce mainly generic 
pharmaceuticals and/or joint ventures between foreign and local companies. Today, 
Middle East countries had to fulfill the obligations of the Trade-Related Aspects of 
Intellectual Property Rights (TRIPS) agreement by January 2005.  
Generic drugs in the Middle East have experienced higher performance due to the 
large numbers of patent expirations, but in the near future this trend will decline as 
well as the number of expiring patents decreases which will give the golden 
opportunity for the multinational companies to enter the market and this will reflect 
the annual growth in the region. Signing the TRIPS by most of Arab countries (except 
Syria and Saudi Arabia) will open the way for the multinational companies to lead the 
market growth in pharmaceutical business. Taking into considerations that the 
currencies in most countries in the region are stable and pegged to the US dollar  
Egypt, Jordan, Lebanon, UAE and Saudi Arabia are all Arab countries but each has its 
own environmental and political characteristics and nature of business. There are 
more than 200 pharmaceutical manufacturers in the Arab World that include private 
or state-owned companies or joint ventures between foreign and local partners, and its 
sales represent about 1.5% of the global pharmaceutical business and the MENA 
region accounts for 2% of the global pharmaceutical sales. 90% of raw materials used 
by Arab pharmaceutical companies are imported from India, China and Brazil. The 
majority of Arab manufacturers produce generic or under-license products, which 
indicate that Arab manufactures depends mainly on R&D of foreign companies. 
While multinational pharmaceutical companies invest about 12 – 20% of their annual 
sales revenue on R&D; Arab pharmaceutical industries invest less than 0.2% of sales 
revenues on research and developing new molecules and these expenditures are 
mostly directed towards new formulations and creating innovative drug-delivery 
systems of existing, off-patent molecules. Due to this, Arab pharmaceutical industries 
are obligated to search for new markets to penetrate in order to continue the annual 
growth 
Egypt; it is biggest population in MENA countries; population of  95 million. 
Egyptian local manufacturers produce about 93% of its pharmaceutical market. Egypt 
is a price sensitive market; its economy depends mainly on tourism, joint ventures 
and/or providing local Egyptian pharmaceutical companies with new products to be 
promoted under license in order to decrease the public cost to the end consumer while 
maintaining acceptable profit margins. Egypt joined the WTO in 1995 and continued 
a decade-long reform process of upgrading its intellectual property laws under the 
U.S/Egypt free trade agreement  
Jordan; the macro-economic fundamentals are sound and many indicators point to 
continuing growth into 2009. The five year average annual GDP growth is 6%. The 
economy is still growing strongly. On the purchasing power parity basis, Jordan’s 
GDP growth performance has shown the ability to deliver tangible growth to its 
inhabitants.  
Jordan is considered the number one largest exporter of pharmaceuticals among Arab 
countries and this industry represents Jordan’s second leading sector registering sales 
of $280 million in 2003. The reason behind focusing on exporting is that the 
Jordanian pharmaceutical market size is small. Jordanian pharmaceutical industries 
spend less than 0.1% of its sales revenues on R&D. Jordanian pharmaceutical 
companies focus mainly on gaining the FDA approval for their products to penetrate 
the US market and use the certificate for promoting items in other countries to 
indicate high quality products.  
Jordan is famous in all aspect of medical care; patients come from Libya, Yemen, and 
Sudan and from some Gulf countries to get the medical care. Jordan has a stable 
political environment in addition its unique location, where it is located beside Iraq, 
Syria, Palestine and Israel, and these countries are very promising. Jordan is 
considered the centre point between these countries allowing the business to expand 
smoothly in the region. The registering time of a new molecule in Jordan is about 180 
days. The currency is stable and is easily transferable. The Jordanian Dinar is stable 
and pegged to the US dollar. During the economic expansion, Jordan has increased its 
foreign exchange reserves substantially to 6.8 billion USD in year 2007 from 2.8 
Billion USD in year 2000. 
Lebanon: has a small market size and because there are a few local Lebanese 
companies; the country depends mostly on pharmaceutical products imports. The 
political environment in this small country that suffered from wars and unstable 
conditions affected the market growth. 
Saudi Arabia is considered the largest market size in Arab countries (Except Egypt). 
Saudi Arabia is one of the most attractive targets for healthcare professionals 
worldwide, where it has shown fast developments in technology in the past few years. 
Lifestyle diseases like obesity, diabetes and hypertension, are among the highest in 
the world; this will elevate the country’s healthcare spending in future. The healthcare 
sector in Saudi Arabia seems very promising and is expected to outpace the growth 
rate of other countries in the Middle East region in coming times. Saudi Arabia 
imports a large amount of semi-finished items to be re-labelled and repackaged. In 
2006, imports were valued at US$1.9 billion, a rise of 12.5% over 2005. Germany and 
Switzerland were the leading suppliers. In contrast, exports amounted to just 
US$102.1 million. Doctors are from different nationalities and medical schools 
(American or British schools of medicine) which would affect the prescription 
behaviour. The domestic production in Saudi Arabia is very low, the majority of the 
market is provided by imports.  
UAE is characterised by the highest price medicines in the region the majority of 
doctors are from the Fareast mainly from Pakistan and India, hospitals are very 
advanced and healthcare providers are unique. There is a marked increase of 
pharmaceutical business in the private sector of UAE which is due to the fact that the 
country decided not to provide any more free medical assistance to foreigners which 
of course increased the healthcare insurance business in the UAE, as medical 
premiums have risen on an average 25-30% owing to rising expensive medical 
claims. It is also important to mention that 80% of the UAE population are foreigner. 
Saudi Arabia and UAE have a significant private market. 
Libya used to purchase medicines without registration (i.e. as tender) but things will 
be changed after the Lockerbie settlement. Libya is an oil producing country and 
depends on importing drugs (generic and original) from Egypt, Jordan and some other 
countries. 
Penetration of MENA region  
There is a huge opportunity for pharmaceutical companies to penetrate the region, 
especially after signing the WTO where the multinational companies can easily 
expand their business by launching new and innovative molecules.  
The governments are strongly moving towards liberalising national economies by 
liberalisation of trade, investment procedures, elimination of trade barriers and 
encouragement of foreign investment by implementing of stronger trademark and 
copyright laws and reduce the import tariffs. The population in Middle East grew by 
2.7% in 2008 and is expected to grow by more than 40% over the next 20 years. The 
top therapeutic categories vary from country to country; for example anti-infective is 
the number one category in Jordan and Saudi Arabia, it is ranked number 4 in Turkey. 
There is a noticeable increase in lifestyle diseases like obesity, diabetes and 
hypertension, and chronic diseases like heart disease and cancer incidence are among 
the highest in the world.  
Local pharmaceutical industries invest less than 0.2% of sales revenues on R&D. 
These expenditures are directed towards new formulations of existing, off-patent 
molecules. Due to this, these manufacturers are obligated to search for new markets to 
penetrate in order to continue the annual growth. The countries’ governments  are 
aiming to improving standard of living by giving better awareness of health issues and 
simplify the health insurers are entering the market. For the healthcare insurance, 
there are new regulations in the region obligate the employers to provide healthcare 
insurance to all employees with their families and this would expand the 
pharmaceutical and healthcare market. In some countries, number of registering 
generics is limited, prices are controlled by health authorities and any changes in the 
prices should be managed by the MOH. Countries like Egypt, Turkey and Iran 
representing more than 60% of the population in the ME. Moreover, the Egyptian 
local manufacturers produce about 93% of its pharmaceutical market. In Saudi 
Arabia, the imports represent 80-85% of the Saudi pharmaceutical market 
Some countries are very promising, like Syria and Iraq; where the unstable political 
conditions and a little data about the market; make it difficult to evaluate the risks of 
penetrating these markets.  Yemen is ranked the sixth in terms of population, and it 
has climbed from being one of the world's poorest countries to the middle-income 
bracket due to oil and unification of North and South Yemen. 45% of the 
pharmaceutical market is considered parallel market (grey market) and import 
illegally from the neighbor countries especially from Egypt. It is also important to 
mention that Egypt has a higher generic penetration and BMI estimates that generic 
drugs account for less than 10% of the GCC pharmaceutical market. Figure (2) 
represents an overview of the ME markets, in relation to the governmental spending 
on healthcare, market growth and population in Turkey, Jordan, Saudi Arabia, Egypt, 
and Lebanon.  
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Jordan: 
Prices are controlled by 
health authorities mainly JFDA. 
First generic priced at 25-30% discount 
to the 
originator 
and any further 
reduction is 
determined by ministries of health 
Figure (2): relationship between average pharmaceutical growth, population and health care spending in Turkey, 
Jordan, Saudi Arabia, Egypt, and Lebanon 
Pricing is determinate according to the added value of product to health services, price 
in neighboring countries, price in country of origin and price of competitors in the 
market. 
Conclusion   
Despite the small market size of Jordanian Pharmaceutical market, but Jordan is 
considered as a strategic place for investment in MENA countries. The stability of 
Jordanian market makes it opportunity to exist in the MENA countries. This 
conference paper is based on the statistics from IMS and internationally recognised 
companies in pharmaceutical markets. The globalisation will motivate investor to 
create opportunities in MENA, and accordingly, the future investment for MNC in 
Jordan is expected to increase within high political turbulence conditions in some 
countries surrounding Jordan.  
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